Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

NCT06021678 is registered in ClinicalTrials.gov with Guangzhou Excelmab Inc. as lead sponsor.

NCT NCT06021678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06021678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Lead sponsor
Guangzhou Excelmab Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 12, 2021
Completion date
December 31, 2025
Enrollment
415 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive non-hodgkin lymphoma